Clinical Usefulness of Endothelial Progenitor Cells in Predicting the Efficacy of Riociguat in Chronic Thromboembolic Pulmonary Hypertension

Overview

Journal Nagoya J Med Sci

Specialty General Medicine

Date 2024 Jul 4

PMID 38962405

Authors

Ryo Imai

Shiro Adachi

Masahiro Yoshida

Shigetake Shimokata

Yoshihisa Nakano

Naoki Okumura

Toyoaki Murohara

Takahisa Kondo

Affiliations

Soon will be listed here.

Abstract

Endothelial dysfunction is important in the pathology of pulmonary hypertension, and circulating endothelial progenitor cells (EPCs) have been studied to evaluate endothelial dysfunction. In patients with chronic thromboembolic pulmonary hypertension (CTEPH), riociguat reportedly increases the number of circulating EPCs. However, the relationship between EPC numbers at baseline and changes in clinical parameters after riociguat administration has not been fully elucidated. Here, we evaluated 27 treatment-naïve patients with CTEPH and analyzed the relationships between EPC number at diagnosis and clinical variables (age, hemodynamics, atrial blood gas parameters, brain natriuretic peptide, and exercise tolerance) before and after riociguat initiation. EPCs were defined as CD45 CD34 CD133 cells and measured by flow cytometry. A low number of circulating EPCs at diagnosis was significantly correlated with increased reductions in mean pulmonary arterial pressure (mPAP) (correlation coefficient = 0.535, = 0.004) and right atrial pressure (correlation coefficient = 0.618, = 0.001) upon riociguat treatment. We then divided the study population into two groups according to the mPAP change: a weak-response group (a decrease in mPAP of 4 mmHg or less) and a strong-response group (a decrease in mPAP of more than 4 mmHg). The number of EPCs at diagnosis was significantly lower in the strong-response group than in the weak-response group ( = 0.022), but there were no significant differences in other clinical variables or in medication profiles. In conclusion, circulating EPC numbers could be a potential predictor of the therapeutic effect of riociguat in CTEPH patients.

References

Doyle M, Tracy R, Parikh M, Hoffman E, Shimbo D, Austin J . Endothelial progenitor cells in chronic obstructive pulmonary disease and emphysema. PLoS One. 2017; 12(3):e0173446. PMC: 5349667. DOI: 10.1371/journal.pone.0173446. View

Galie N, Kim N . Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7):571-6. DOI: 10.1513/pats.200605-113LR. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Brenot P, Jais X, Taniguchi Y, Alonso C, Gerardin B, Mussot S . French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019; 53(5). PMC: 6853610. DOI: 10.1183/13993003.02095-2018. View

Sun H, Li G, DU Z, Bing Z, Ji Z, Luo G . The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease. BMC Pediatr. 2019; 19(1):502. PMC: 6918598. DOI: 10.1186/s12887-019-1884-x. View

Dierick F, Solinc J, Bignard J, Soubrier F, Nadaud S . Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension. Cells. 2021; 10(6). PMC: 8226806. DOI: 10.3390/cells10061338. View

Yao W, Firth A, Sacks R, Ogawa A, Auger W, Fedullo P . Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009; 296(6):L870-8. PMC: 2692803. DOI: 10.1152/ajplung.90413.2008. View

Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A . HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001; 108(3):399-405. PMC: 209363. DOI: 10.1172/JCI13131. View

Garcia-Lucio J, Tura-Ceide O, Del Pozo R, Blanco I, Pizarro S, Ferrer E . Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension. Int J Cardiol. 2016; 228:238-243. DOI: 10.1016/j.ijcard.2016.11.175. View

10.

Wang W, Wen L, Song Z, Shi W, Wang K, Huang W . Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis. Clin Cardiol. 2019; 42(8):741-752. PMC: 6671827. DOI: 10.1002/clc.23212. View

11.

Diller G, Van Eijl S, Okonko D, Howard L, Ali O, Thum T . Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation. 2008; 117(23):3020-30. DOI: 10.1161/CIRCULATIONAHA.108.769646. View

12.

Menegazzo L, Albiero M, Avogaro A, Fadini G . Endothelial progenitor cells in diabetes mellitus. Biofactors. 2012; 38(3):194-202. DOI: 10.1002/biof.1016. View

13.

Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard L, Marchesan D . Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009; 180(8):780-7. PMC: 2778151. DOI: 10.1164/rccm.200810-1662OC. View

14.

Krenning G, Dankers P, Drouven J, Waanders F, Franssen C, van Luyn M . Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol. 2009; 296(6):F1314-22. PMC: 2692451. DOI: 10.1152/ajprenal.90755.2008. View

15.

Riedel M, Stanek V, Widimsky J, PREROVSKY I . Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982; 81(2):151-8. DOI: 10.1378/chest.81.2.151. View

16.

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4):434-8. DOI: 10.1038/7434. View

17.

Yamamoto K, Nishimura R, Kato F, Naito A, Suda R, Sekine A . Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2019; 299:263-270. DOI: 10.1016/j.ijcard.2019.07.017. View

18.

Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H . Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 2006; 113(11):1442-50. DOI: 10.1161/CIRCULATIONAHA.105.583732. View

19.

Ghofrani H, DArmini A, Grimminger F, Hoeper M, Jansa P, Kim N . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-29. DOI: 10.1056/NEJMoa1209657. View

20.

Junhui Z, Xingxiang W, Guosheng F, Yunpeng S, Furong Z, Junzhu C . Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med. 2008; 102(7):1073-9. DOI: 10.1016/j.rmed.2007.12.030. View